Share Consolidation Update

RNS Number:3554L
Amarin Corporation Plc
08 January 2008



           ISSUE OF ORDINARY SHARES AND ANNOUNCEMENT OF TIMETABLE FOR
                     PROPOSED 10 FOR 1 SHARE CONSOLIDATION



LONDON, United Kingdom (January 8, 2008) - Amarin Corporation plc ("Amarin" or
the "Company") today announces that it has made an application to the London
Stock Exchange and the Irish Stock Exchange to list on AIM and IEX respectively
975,000 Ordinary Shares of £0.05 each in the capital of the Company.  These
Ordinary Shares are to be issued in the form of American Depositary Shares 
("ADSs") to ProSeed Capital Holdings CVA in respect of fees due for investment
banking advice provided to the Company on the acquisition of Ester Neurosciences
Limited



Following the above issue, the Company's issued share capital will consist of
140,032,370 Ordinary Shares of £0.05 each with voting rights, which represents
the total number of voting rights in the Company.



The Company also announces the timetable for the proposed consolidation of every
ten existing Ordinary Shares of £0.05 each into one Ordinary Share of £0.50
each, subject to the passing of an ordinary resolution at a General Meeting of
shareholders to be held on 17 January 2008 (as set out in a Notice of General
Meeting sent to shareholders on 12 December 2007).  The Company will apply for
14,003,237 Ordinary Shares of £0.50 each to be admitted to trading on AIM and
IEX.  Subject to the passing of the resolution at the General Meeting, admission
of the Ordinary Shares of £0.50 each to AIM and IEX is expected to take place on
18 January 2008, following which the Company will have 14,003,237 Ordinary
Shares of £0.50 each in issue.


The Company confirms the planned timetable for the proposed consolidation is as 
follows:



General Meeting to approve share consolidation          11.00am GMT on 
                                                        17 January 2008

Share consolidation Record Date                         5.00pm GMT on 
                                                        17 January 2008

Dealings commence on AIM and IEX in
Ordinary Shares of £0.50 each                           18 January 2008



Crediting of uncertificated Ordinary Shares
of £0.50 each to CREST accounts (where applicable)      18 January 2008



Despatch of share certificates for
Ordinary Shares of £0.50 each (where
applicable)                                             25 January 2007





Subject to the passing of the resolution at the General Meeting, with effect
from 18 January 2008, the Ordinary Shares of £0.50 each will trade under the new
ISIN GB00B29VL935.



Following the proposed consolidation outlined above, each ADS will continue to
represent one Ordinary Share.  Accordingly, with effect from 18 January 2008,
the proposed consolidation will have a corresponding effect on all outstanding
ADSs.  The corresponding effective date for ADSs will be 18 January 2008.



Amarin has notified Nasdaq that the proposed consolidation will take effect on
18 January 2008.



About Amarin

Amarin is committed to improving the lives of patients suffering from central
nervous system and cardiovascular diseases. Our goal is to be a leader in the
research, development and commercialization of novel drugs that address unmet
patient needs.



Amarin's CNS development pipeline includes the recently acquired myasthenia
gravis clinical program and preclinical programs in neuromuscular, neuronal
degenerative and inflammatory diseases; Miraxion for Huntington's disease; two
programs in Parkinson's disease; one in epilepsy; and one in memory. Amarin is
initiating a series of cardiovascular preclinical and clinical programs to
capitalize on the known therapeutic benefits of essential fatty acids in
cardiovascular disease. Amarin also has two proprietary technology platforms, a
lipid-based technology platform for the targeted transport of molecules through
the liver and/or to the brain, and a unique mRNA technology based on cholinergic
neuromodulation.



Amarin has its primary stock market listing in the U.S. on the NASDAQ Capital
Market ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN")
and IEX ("H2E"), respectively.



Contacts:

Amarin [phone]
Thomas Lynch Chief Executive Officer
Alan Cooke President and Chief Operating Officer
[e-mail]


Investors:
Lippert/Heilshorn & Associates, Inc.
Anne Marie Fields [phone]
Bruce Voss [phone]



Media:
Powerscourt [phone]
Rory Godson
Sarah Daly



Davy: [phone]
Ivan Murphy
Fergal Meegan



                                     Ends.






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCILFFDLIITIIT